Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pamrevlumab versus placebo study in idiopathic pulmonary fibrosis
jRCT2051210169Phase 3Suspended
- Sponsor
- FibroGen
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Pamrevlumab with Placebo (2 arms). Primary endpoint: Change in forced vital capacity. Started Jan 2022; status: suspended.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2051210169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210169.